ESSA Pharma Inc. Files 8-K for Other Events
| Field | Detail |
|---|---|
| Company | Essa Pharma Inc. |
| Form Type | 8-K |
| Filed Date | Oct 3, 2025 |
| Risk Level | low |
| Pages | 6 |
| Reading Time | 8 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
ESSA Pharma filed an 8-K for 'Other Events' on 9/30/25. Details TBD.
AI Summary
ESSA Pharma Inc. filed an 8-K on October 3, 2025, reporting an event that occurred on September 30, 2025. The filing pertains to 'Other Events' and does not disclose specific financial transactions or material changes beyond this classification.
Why It Matters
This 8-K filing indicates that ESSA Pharma Inc. has reported an event, but the lack of specific details means investors cannot yet assess its potential impact on the company.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' without immediate disclosed financial impact, making the risk level low.
Key Players & Entities
- ESSA Pharma Inc. (company) — Registrant
- September 30, 2025 (date) — Date of earliest event reported
- October 3, 2025 (date) — Filing Date
FAQ
What specific event is ESSA Pharma Inc. reporting under 'Other Events'?
The filing does not specify the nature of the 'Other Events' beyond its classification.
When did the reported event occur?
The earliest event reported occurred on September 30, 2025.
What is the filing date of this 8-K?
This Form 8-K was filed as of October 3, 2025.
Where is ESSA Pharma Inc. incorporated?
ESSA Pharma Inc. is incorporated in British Columbia, Canada.
What is the principal executive office address for ESSA Pharma Inc.?
The principal executive offices are located at Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5.
Filing Stats: 1,898 words · 8 min read · ~6 pages · Grade level 17.3 · Accepted 2025-10-03 06:02:22
Filing Documents
- tm2527481d3_8k.htm (8-K) — 37KB
- 0001104659-25-096306.txt ( ) — 205KB
- epix-20250930.xsd (EX-101.SCH) — 3KB
- epix-20250930_lab.xml (EX-101.LAB) — 33KB
- epix-20250930_pre.xml (EX-101.PRE) — 22KB
- tm2527481d3_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On September 30, 2025, a putative class action complaint was filed in the Superior Court of the State of California County of San Mateo against ESSA Pharma Inc. (the " Company "), captioned Nathan O'Neil, et al. v. ESSA Pharma Inc. (the " Complaint "). The Complaint, which purports to be brought on behalf of a class of all persons and entities who purchased common shares of the Company (" Common Shares ") on August 25, 2025, before the Company issued its August 25, 2025 press release alleges, among other things, breach of contract and promissory estoppel claims based on the disclosures made by the Company in its August 14, 2025 Form 8-K. The Company believes that it has valid defenses to the claims alleged in the Complaint and intends to defend the lawsuit vigorously, but there is no guarantee that the Company will prevail. At the time of filing, the outcome of this matter and any possible related losses are not estimable or probable.
Forward Looking Statements
Forward Looking Statements This communication, and any related oral statements, contains certain information which, as presented, constitutes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws (collectively, " forward-looking statements "). Forward-looking statements include, but are not limited to, statements that relate to future events and often address expected future business and financial performance, containing words such as "anticipate," "believe," "plan," "estimate," "expect," and "intend," statements that an action or event "may," "might," "could," "should," or "will" be taken or occur, or other similar expressions and include, but are not limited to, statements regarding the proposed timing and completion of the Company's previously announced Business Combination Agreement with XenoTherapeutics Inc. (" Xeno "), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding Common Shares (the " Transaction "), the outcome of O'Neil, et al. v. ESSA Pharma Inc. or any other lawsuits that may be filed, and other statements that are not statements of historical facts. In this communication, these forward-looking Special Meeting, the expected date of closing of the Transaction and the potential benefits thereof, the Complaint, the Company's business and industry, management's beliefs and certain assumptions made by the Company, all of which are beyond the ability of the Company to control or predict, and which may cause the Company's actual results, performance or achievements to be materially different from those expressed or implie
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ESSA PHARMA INC. (Registrant) Date: October 3, 2025 By: /s/ David Wood Name: David Wood Title: Chief Financial Officer